Promoting Patient-Centeredness in Opioid Deprescribing: a Blueprint for De-implementation Science
- PMID: 33145692
- PMCID: PMC7728868
- DOI: 10.1007/s11606-020-06254-7
Promoting Patient-Centeredness in Opioid Deprescribing: a Blueprint for De-implementation Science
Abstract
A downward trend in opioid prescribing between 2011 and 2018 has brought per-capita opioid prescriptions below the levels of 2006, the earliest year for which the Centers for Disease Control and Prevention has published data. That trend has affected roughly ten million patients who previously received long-term opioid therapy. Any effort to reduce or replace a prior health practice is termed de-implementation. We suggest that the evaluation of opioid prescribing de-implementation has been misdirected, within US policy and health research, resulting in detrimental impacts on patients, their families and clinicians. Policymakers and implementation scientists can address these deficiencies in how we study and how we perform opioid de-implementation by applying an implementation science framework: the Consolidated Framework for Implementation Research. The Consolidated Framework lays out relevant domains of activity (internal, external, etc.) that influence implementation processes and outcomes. It can deepen our understanding of how policies are chosen, communicated, and carried out. Policymakers and researchers who embrace this framework will need a better approach to measuring success and failure in health care where both pain and opioids are concerned. This would involve shifting from a reductive focus on opioid prescription counts toward measures that are more effective, holistic, and patient-centered.
Conflict of interest statement
Dr. Kertesz affirms past personal ownership of stock in Merck and Abbott pharmaceutical companies, sold in December of 2017, and not exceeding 5% of his assets at the time. Dr. Kertesz holds stock in CVS Caremark, Thermo Fisher, and Zimmer Biomet, not exceeding 5% of his assets. Dr. Kertesz reports his spouse holds equity in Merck, Abbot, Thermo Fisher, and Johnson and Johnson, in her private assets, not exceeding 10% of her assets. Dr. Kertesz receives income from UpToDate, Inc. Dr. Darnall is the recipient of a research award from the Patient-Centered Outcomes Research Institute® (#1610-3700), author royalties from multiple books, and compensation as chief scientific advisor at AppliedVR. Dr. Varley receives part-time income from Heart Rhythm Clinical and Research Solutions.
Figures

References
-
- CDC National Center for Injury Prevention and Control. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published November 1, 2019. Available at: https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-rep.... Accessed January 24, 2020.
-
- Rubin R. Limits on opioid prescribing leave patients with chronic pain vulnerable. JAMA. 2019;321(21):2059–2062. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources